Tryp Therapeutics Set To Finalize Merger With Exopharm, Announces Trading Halt Ahead Of ASX Listing
Tryp Therapeutics Set To Finalize Merger With Exopharm, Announces Trading Halt Ahead Of ASX Listing
Tryp Therapeutics Inc. (OTCQB:TRYPF), a Canadian biotech leader in psychedelics, has officially received approval from Exopharm Limited shareholders for their strategic merger, paving the way for a new entity, Tryptamine Therapeutics Limited.
加拿大迷幻药生物技术领导者Tryp Therapeutics Inc.（OTCQB: TRYPF）的战略合并已正式获得Exopharm Limited股东的批准，为新实体色胺疗法有限公司铺平了道路。
Key Merger Dates And Trading Halt
关键合并日期和暂停交易
This approval follows a decisive plan of arrangement initially inked in December last year. The completion is set for May 1, 2024, with trading anticipated to commence on the Australian Securities Exchange (ASX) under the ticker "TYP" by mid-May.
这项批准是在去年12月最初签署的一项决定性的安排计划之后获得的。交易定于2024年5月1日完成，预计将于5月中旬在澳大利亚证券交易所（ASX）开始交易，股票代码为 “TYP”。
In preparation for this transition, Tryp will voluntarily halt trading of its shares on the Canadian Securities Exchange and the OTCQB Venture Market starting April 29, 2024. Following the merger, Tryp shares will be delisted as the company transitions fully to the ASX platform.
为了为这一过渡做准备，Tryp将从2024年4月29日起自愿停止其在加拿大证券交易所和OTCQB风险投资市场的股票交易。合并后，随着公司完全过渡到澳大利亚证券交易所平台，Tryp的股票将退市。
Merger Details And Shareholder Benefits
合并细节和股东权益
The arrangement, valued at approximately CA$12.8 million ($9.3 million), offers Tryp shareholders a significant premium on their investment, with Exopharm issuing 4.52 ordinary shares for each Tryp share. This merger marks a significant premium based on previous closing prices and aligns with Tryp's strategic vision to enhance shareholder value and expand its clinical programs.
该安排价值约1,280万加元（合930万美元），为Tryp股东提供了可观的投资溢价，Exopharm为Tryp每股发行4.52股普通股。根据之前的收盘价，此次合并标志着可观的溢价，符合Tryp提高股东价值和扩大其临床计划的战略愿景。
Strategic Goals And Expansion Into The Australian Market
战略目标和向澳大利亚市场的扩张
When the plan of arrangement was announced in December, Tryp's CEO Jason Carroll, highlighted the merger as a milestone that "heralds a new era," aiming to leverage the combined strength of both companies to enhance access to capital and respond dynamically to Australia's evolving psychedelics regulations.
在12月宣布安排计划时，Tryp首席执行官杰森·卡罗尔强调此次合并是 “预示着新时代的到来” 的里程碑，旨在利用两家公司的综合实力来增加获得资本的机会，并动态应对澳大利亚不断变化的迷幻药监管。
This strategic expansion into the Australian market comes as both companies aim to solidify their footprint in the global biotech landscape, benefiting from Australia's robust platform for biotechnological advancements.
此次对澳大利亚市场的战略扩张是在两家公司都希望从澳大利亚强大的生物技术进步平台中巩固其在全球生物技术领域的足迹之际进行的。
Action Required For Shareholders
股东需要采取的行动
Registered Tryp shareholders are urged to complete the necessary formalities by submitting their shares and the related letter of transmittal to Computershare Investor Services Inc., as outlined in the company's guidance.
敦促注册的Tryp股东完成必要的手续，如公司指南中所述，向Computershare投资者服务公司提交股票和相关的送文函。
Related News
相关新闻
- Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
- Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia
- Psyched：1亿美元用于摇头丸疗法、弗吉尼亚州基金、2024年观察名单、改革更新等
- Tryp Therapeutics在治疗肠易激综合征和纤维肌痛的新试验中探索迷幻药的潜力